The revised WHO classification 2016 of central nervous system tumours incorporates molecular biomarkers in addition to histological features in an « integrated diagnosis ». Thus, it refines classification with more homogenous diagnosis groups in order to improve prognosis and to guide treatment, notably for gliomas. This article firstly summarized the new concept of this revised classification, some basis of the molecular genetics of gliomas and practical application of the « integrated diagnosis ». It analyses the impact of this classification on the diagnosis and outcome of gliomas performed at the University Institute of Pathology - CHUV, Lausanne from October 2015 to November 2016.